Search Results for “EC” – Page 179 – media

A strong alliance! Bluesail Medical joins hands with Wanhua Chemical to welcome major opportunities and benefits

In the fields of medicine, scientific research, manufacturing, etc., professional-grade disposable consumables often play a pivotal role. These seemingly simple but crucial products not only bear the heavy responsibility of ensuring safety and improving efficiency, but also require the deep integration of cutting-edge technological innovation and practical applications, which also makes the research and development of high-end disposable consumables a complex and sophisticated system engineering. However, technological innovation does not exist in isolation. It must be rooted in actual needs and requires strong alliances between powerful companies. Now, this practice has another typical example of cooperation. Recently, Bluesail Medical and Wanhua Chemical signed a strategic cooperation agreement at Wanhua Chemical’s Cishan headquarters and held a joint innovation laboratory unveiling ceremony. The content of this cooperation is mainly for both parties to give full play to their strengths and carry out deep integration, namely “Wanhua Chemical’s polyurethane industry chain advantages and ...
- Source: drugdu
- 76
- October 25, 2024
Everest Medicines Announces Taiwan’s Approval of the World’s First New Drug Application for Nervosa® for the Treatment of IgA Nephropathy

Everest Medicines (HKEX 1952.HK), a biopharmaceutical company focused on the research and development, clinical development, manufacturing and commercialization of innovative drugs, announced today that the Taiwan Food and Drug Administration (TFDA) has approved NEFECON® (budesonide enteric-coated capsules, NEFECON®) for the treatment of adult patients with primary immunoglobulin A nephropathy (IgA nephropathy) at risk of progression to delay renal function decline by 1, with no baseline proteinuria level restriction. This means that NEFECON®, as the world’s first and only causal treatment for IgA nephropathy fully approved by the U.S. Food and Drug Administration (FDA), has further expanded its coverage, bringing new hope to more Chinese IgA nephropathy patients. The results of the NefIgArd Phase 3 global clinical trial showed that compared with placebo, NefIgArd® not only brought about a lasting decrease in proteinuria and reduced the risk of microscopic hematuria, but more importantly, it showed clinically relevant and statistically significant treatment ...
- Source: drugdu
- 63
- October 25, 2024
AI+drug target discovery | Insitro and Eli Lilly reach strategic agreement to jointly promote new therapies for metabolic diseases

Zhiyao Bang October 23, 2024 09:01 Shanghai On October 9, 2024, insitro, a new drug development company that supports machine learning, announced the signing of three strategic agreements with Eli Lilly, focusing on developing potential new drugs for the treatment of metabolic diseases, including metabolic dysfunction associated fatty liver (MASLD), based on the targets identified by insitro using the company’s AI based platform.Metabolic diseases, including MASLD, affect millions of people worldwide, but effective treatment options are still limited. The current treatment mainly treats the symptoms rather than the root cause. This collaboration aims to combine Insitro’s machine learning platform with Lilly’s expertise in cutting-edge drug delivery and metabolic disease biology to change existing models. According to the first two agreements, Insitro can choose to license Lilly’s proprietary, clinically advanced ternary N-acetylglucosamine (GalNAc) delivery technology, which will be combined with two different small interfering RNA (siRNA) molecules discovered and developed by ...
- Source: drugdu
- 61
- October 24, 2024
GE Healthcare launches its first CT production line in the country

Recently, GE Healthcare launched its first CT production line in France, marking a significant expansion of the company’s business at its Booker factory in the Yvelines department of France. It is reported that the new production line was announced in 2023 with the aim of improving the company’s agility, reducing carbon emissions, and better serving European customers. At present, the first scanner assembled in France, the Revolution Maxima CT, has been installed in the emergency department of Montargis Hospital Center in Loiret. The assembly of Revolution Maxima CT at Buc factory includes all functions and X-ray testing, system configuration, and direct delivery to European customers, which helps simplify the supply chain. It is understood that the new production line is part of GE Healthcare’s “In Europe for Europe” program, which is expected to reduce carbon emissions related to scanner transportation in Europe by 84%. This reduction is mainly due to ...
- Source: drugdu
- 71
- October 24, 2024
Boston Scientific’s’ 2 Medical Devices’ Approved for Market by FDA

On October 21st, according to foreign media Fierce Biotech, the FARAWAVE NAV ablation catheter and Faraview software integrated with Boston Scientific’s navigation function have been approved by the US Food and Drug Administration (FDA). It is reported that the above two products have been officially launched in the United States, forming part of the Boston Scientific Farapulse Pulsed Field Ablation (PFA) system, providing a new visualization solution for cardiac ablation surgery. New features added The FARAWAVE NAV ablation catheter is an upgrade based on the previous generation PFA product FARAPULSE. It looks very similar to the FARAPULSE ablation catheter in appearance, but the new generation product has many new features that were not present in the previous generation product – magnetic navigation function and equipped with a dedicated 3D FARAVIEW module (software). Therefore, this also enables the FARAWAVE NAV ablation catheter to have both ablation and mapping functions:  Ablation ...
- Source: drugdu
- 66
- October 24, 2024
When Hengrui Medicine “gave up” going overseas independently

Going overseas is not only a dream, but also a big adventure that Hengrui Medicine has to take. Even under the new measurement standards, there is such a voice that the success of going overseas will be the key to determining whether Hengrui Medicine can maintain its “number one” status. Indeed, Hengrui Medicine, which has accelerated its innovation transformation, has come to a crossroads. First, relying on the domestic market in the past, Hengrui Medicine may not be in a hurry to layout overseas markets. However, with the involution of domestic innovative drugs and pharmaceutical companies going overseas to find incremental growth, internationalization has also been raised to a more important level. Although Hengrui Medicine proposed the direction of “internationalization” as early as in its 2020 annual report, its internationalization has not been smooth in the past few years. Secondly, carrelizumab has already fallen behind, and the internationalization of PD-1 ...
- Source: drugdu
- 57
- October 24, 2024
Going overseas in the storm of price cuts

This year, “going overseas” is still a hot keyword in the medical device industry. Especially at present, the domestic medical device market has entered a plateau period, and local “roll kings” are increasingly aware of the importance of going overseas. A positive signal is that the recognition of Chinese medical devices in overseas markets is constantly rising. At the just-concluded CMEF Autumn Exhibition, participants could clearly feel that international friends have become more enthusiastic about the Chinese medical device exhibition. According to the organizer, the number of pre-registrations for international visitors at this year’s exhibition exceeded twice that of the same period last year. On the background walls of the booths of some local exhibitors, large-scale introductions to companies and products and services are printed in English, which can be said to have spared no effort in attracting overseas attention. The cost advantages of Chinese medical devices and the product ...
- Source: drugdu
- 58
- October 24, 2024
Jixing Announces that the National Medical Products Administration has accepted the New Drug Marketing Authorization Application for Aficamten Tablets

October 18, 2024, Shanghai, China – Jixing Pharmaceuticals (hereinafter referred to as “Jixing”), a biotechnology company committed to bringing innovative science and drugs to patients suffering from serious life-threatening cardiometabolic diseases, today Announced that the Center for Drug Evaluation (CDE) of the National Medical Products Administration has officially accepted the new drug marketing application for Aficamten tablets for the treatment of symptomatic obstructive hypertrophic cardiomyopathy (oHCM). Aficamten is a new generation of selective small molecule cardiac myosin inhibitor under development. Its treatment of oHCM has been granted breakthrough therapy designation by the US Food and Drug Administration (FDA) and the China National Medical Products Administration. This new drug marketing application is based on the positive results of the pivotal global Phase 3 clinical study SEQUOIA-HCM. A total of 282 patients with obstructive HCM were enrolled in SEQUOIA-HCM. The study results showed that treatment with Aficamten significantly improved patients’ exercise capacity ...
- Source: drugdu
- 55
- October 24, 2024
Sufficient Supply of Influenza Vaccines in Shandong; Elderly Vaccination Rate at 54.57%

On October 22, the Shandong Provincial Government Information Office held a press conference to introduce the province’s efforts in enhancing the integration of healthcare and elderly care, as well as promoting healthy aging. It was reported that Shandong currently has a sufficient supply of influenza vaccines, having completed 2.67 million doses of vaccinations, with elderly individuals accounting for 54.57% of those vaccinated. As the weather turns colder, infectious diseases such as influenza and pneumonia enter their peak season, and the elderly are a major susceptible group. It was noted that over 3,200 medical institutions in Shandong have activated a real-time monitoring and reporting network for infectious diseases, focusing particularly on the incidence of diseases among the elderly and other key populations. Vaccination against influenza and pneumonia not only reduces infection risks but also effectively lowers the incidence of severe cases, making it one of the primary measures for the prevention ...
- Source: drugdu
- 58
- October 24, 2024
Arab Health

Organiser：Informa Markets Time： January 27 – 30, 2025 Address：Sheikh Zayed Road Convention Gate Dubai, UAE – United Arab Emirates Exhibition hall：Dubai World Trade Centre Product range: Medical Devices & Equipment: Medical electronic equipment, medical ultrasound equipment, medical X-ray equipment, medical optical instruments, clinical laboratory analysis instruments, dental equipment and materials, operating room, emergency room, and consulting room equipment and appliances, disposable medical supplies, medical dressings and hygienic materials, various surgical instruments, medical healthcare equipment and supplies, traditional Chinese medicine instruments and rehabilitation appliances, hemodialysis equipment, anesthesia and respiratory equipment, etc. Household Healthcare Products & Small Healthcare Devices: Household health and wellness products, small household diagnostic, monitoring, and treatment instruments, rehabilitation/physiotherapy instruments and supplies, electronic medical instruments, dental appliances, hospital office supplies, sports medicine supplies. Bulk Drugs, Proprietary Chinese Medicines, Pharmaceuticals & Healthcare: Therapeutic, rehabilitative, and healthcare products and supplies with Oriental medicine characteristics. About SLAS： The Arab Health Exhibition ...
- Source: drugdu
- 54
- October 24, 2024

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.